Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to improve human health and drive discovery in the life sciences, today announced the formation of a clinical advisory board to help the company advance its 3D genomics technologies into the clinical oncology and biopharmaceutical markets.
Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022ABX196 phase 1/2 study results for the treatment of hepatocellular carcinoma (HCC) were selected for a presentation at the ASCO Gastrointestinal Cancers Symposium 2022ABX196 at a max.
19.01.2022 Abivax s phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022 | ABIVAX | News | Nachricht | Mitteilung